A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (OSAT)

Novartis

Status: Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Treatments: Other: everolimis

Study type: Observational

Funder types: Industry

Identifiers

NCT01390519

CRAD001LNO03

Details and patient eligibility

About

This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of Afinitor® in a pure 2.line setting.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Confirmed diagnosis of advanced renal cell cancer
• Progression on or after one VEGF -TKI (e.g. sunitibin, sorafenib)
• Written informed consent

Exclusion criteria

None

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

30 participants in 1 patient group

Afinitor

Description:

Afinitor

Treatment:

Other: everolimis